SAN JOSE, Calif., Sept. 8,
2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a
biotechnology company focused on the treatment and prevention of
cancer and infectious diseases, announced today that Dr.
Amit Kumar, Anixa's Chief Executive
Officer, will present at the virtual H.C. Wainwright
23rd Annual Global Investment Conference being held
September 13-15, 2021.
During the presentation, Dr. Kumar will provide an overview of
Anixa's business and highlight recent corporate achievements,
including the recent FDA clearance to proceed with clinical trials
of its CAR-T based ovarian cancer therapeutic program, as well as
anticipated milestones in its breast cancer vaccine clinical
trials. Company management will also be available to
participate in online one-on-one meetings with conference
attendees.
Details of Anixa's presentation are as follows:
Event:
H.C. Wainwright 23rd Annual Global Investment
Conference
Date & Time: On demand, beginning
7:00 a.m. ET, Monday, September 13, 2021
Webcast link:
https://journey.ct.events/view/16886dde-86ea-4346-851b-89172199886e
An archive of the webcast will remain available for 90 days
after the event.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company developing a number of
programs addressing cancer and infectious disease. Anixa's
therapeutics portfolio includes a cancer immunotherapy program
which uses a novel type of CAR-T, known as chimeric endocrine
receptor T-cell (CER-T) technology, and a Covid-19 therapeutics
program focused on inhibiting certain viral protein function.
The company's vaccine portfolio includes a vaccine to prevent
breast cancer, and specifically triple negative breast cancer
(TNBC), the most deadly form of the disease, and a vaccine to
prevent ovarian cancer. These vaccine technologies focus on
immunizing against specific proteins that have been found to be
expressed in certain forms of cancer. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301371197.html
SOURCE Anixa Biosciences, Inc.